论文部分内容阅读
目的观察替比夫定联合强肝健脾方治疗肝郁脾虚型慢性乙型肝炎的临床疗效。方法将186例患者随机分为两组。治疗组96例给予强肝健脾方联合替比夫定治疗,对照组90例单纯用替比夫定治疗。治疗第4周、12周、24周、48周后分别观察两组患者谷丙转氨酶(ALT)复常率、HBV-DNA转阴率、HBe Ag转阴率。结果治疗组治疗第4周ALT复常率优于对照组(P<0.05),但在治疗第12周、24周、48周,两组ALT复常率比较差异均无统计学意义(P>0.05);两组在治疗第4周、12周的HBV-DNA阴转率和第12周、24周、48周HBe Ag转阴率比较,差异均有统计学意义(P<0.05)。结论替比夫定联合强肝健脾方能明显改善肝功能,并有一定抗乙型肝炎病毒的作用,疗效肯定。
Objective To observe the clinical efficacy of telbivudine combined with Qianggan Jianpi Decoction in treating chronic hepatitis B with liver depression and spleen deficiency syndrome. Methods 186 patients were randomly divided into two groups. In the treatment group, 96 cases were treated with Qianggan Jianpi prescription combined with telbivudine, and 90 cases in the control group were treated with Telbivudine alone. At 4, 12, 24 and 48 weeks after treatment, the alanine aminotransferase (ALT) normalization rate, HBV-DNA negative rate and HBeAg negative rate were observed in both groups. Results The ALT recovery rate in the fourth week of treatment was better than that of the control group (P <0.05), but there was no significant difference in the ALT recovery between the two groups at the 12th week, the 24th week and the 48th week (P> 0.05). The negative conversion rate of HBV-DNA in the fourth and the twelfth week of the two groups was statistically significant (P <0.05) compared with the negative rate of HBeAg in the 12th week, the 24th week and the 48th week. Conclusion The combination of telbivudine and qiangganjianpi can significantly improve liver function, and have a certain anti-hepatitis B virus effect, the effect is sure.